A Phase 1 interventional study of Trazodone HCl and Trazodone HCl in Healthy, sponsored by Labopharm Inc.. Completed. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2012-04-27.
Sponsored by Labopharm Inc. · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The objectives of this study were:
Labopharm Inc. is the lead sponsor of 19 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
For females, the following conditions are to be met:
is of , and all of the following conditions are met:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Test product 1 and Test product 2 are two different prototype formulations of Trazodone Contramid® OAD (once a day)
Drug: Trazodone HCl
Test product 1 and Test product 2 are two different prototype formulations of Trazodone Contramid® OAD (once a day)
Drug: Trazodone HCl
Drug: Trazodone HCl
Drug: Trazodone HCl
The dosage of trazodone.HCl during this treatment phase was a single oral dose of 300 mg (one CR tablet) at 07:30 (after an overnight fast of at least 10 hours) on clinic days.
The dosage of trazodone.HCl during this treatment phase was a single oral dose of 300 mg (one CR tablet) at 07:30 (after an overnight fast of at least 10 hours) on clinic days.
Also known as: Oleptro
The dosage of trazodone.HCl during this treatment phase was 2 oral doses of 150 mg each: one controlled-release (CR) tablet at 07:30 (after an overnight fast of at least 10 hours) and 19:30 (after a fast of at least 2 hours) on clinic days.
The dosage of trazodone.HCl during this treatment phase was three oral doses of 100 mg each: one immediate-release (IR) tablet at 07:30 (after an overnight fast of at least 10 hours), 15:30 and 23:30 (both dosages after a fast of at least 2 hours) on clinic days.
Bioequivalence Based on AUC(0-t)
AUC(0-t) = Area under the plasma concentration curve vs (versus) time data pairs, where t is the time of the last quantifiable concentration. Measured in nanogram x hours per milliliter (ng\*h/mL).
Time frame: 72 hours
Bioequivalence Based on AUC(0-∞)
AUC(0-∞) = Area under the plasma concentration curve vs time data pairs, with extrapolation to infinity (∞). Measured in nanogram x hours per milliliter (ng\*h/mL).
Time frame: 72 hours
Bioequivalence Based on Cmax
Cmax = Maximum plasma concentration. Measured in nanogram per milliliter (ng/mL).
Time frame: 72 hours
Apparent Terminal Half-life (t½.z)
Apparent terminal half-life (t½.z) of trazodone in hours
Time frame: 72 hours
Time to the Maximum Concentration (Tmax)
Time frame: 72 hours
Apparent First Order Terminal Rate Constant [λz]
Apparent First order terminal rate constant \[λz\] of trazodone in plasma expressed in 1/hours.
Time frame: 72 hours
| Milestone | Trazodone Contramid® OAD (Prototype 1) First | Trazodone Contramid® OAD (Prototype 2) First | Triticco® First | Desyrel® First |
|---|---|---|---|---|
| Started | 6 | 6 | 6 | 6 |
| Completed | 6 | 6 | 5 | 6 |
| Not completed | 0 | 0 | 1 | 0 |
| Withdrew: Adverse event | 0 | 0 | 1 | 0 |
| Milestone | Trazodone Contramid® OAD (Prototype 1) First | Trazodone Contramid® OAD (Prototype 2) First | Triticco® First | Desyrel® First |
|---|---|---|---|---|
| Started | 6 | 6 | 5 | 6 |
| Completed | 5 | 6 | 5 | 6 |
| Not completed | 1 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 1 | 0 | 0 | 0 |
| Milestone | Trazodone Contramid® OAD (Prototype 1) First | Trazodone Contramid® OAD (Prototype 2) First | Triticco® First | Desyrel® First |
|---|---|---|---|---|
| Started | 5 | 6 | 5 | 6 |
| Completed | 5 | 6 | 4 | 6 |
| Not completed | 0 | 0 | 1 | 0 |
| Withdrew: Adverse event | 0 | 0 | 1 | 0 |
| Milestone | Trazodone Contramid® OAD (Prototype 1) First | Trazodone Contramid® OAD (Prototype 2) First | Triticco® First | Desyrel® First |
|---|---|---|---|---|
| Started | 5 | 6 | 4 | 6 |
| Completed | 5 | 6 | 3 | 6 |
| Not completed | 0 | 0 | 1 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 1 | 0 |
| Milestone | Trazodone Contramid® OAD (Prototype 1) First | Trazodone Contramid® OAD (Prototype 2) First | Triticco® First | Desyrel® First |
|---|---|---|---|---|
| Started | 5 | 6 | 3 | 6 |
| Completed | 5 | 6 | 3 | 6 |
| Not completed | 0 | 0 | 0 | 0 |
| Milestone | Trazodone Contramid® OAD (Prototype 1) First | Trazodone Contramid® OAD (Prototype 2) First | Triticco® First | Desyrel® First |
|---|---|---|---|---|
| Started | 5 | 6 | 3 | 6 |
| Completed | 4 | 6 | 3 | 6 |
| Not completed | 1 | 0 | 0 | 0 |
| Withdrew: Adverse event | 1 | 0 | 0 | 0 |
| Milestone | Trazodone Contramid® OAD (Prototype 1) First | Trazodone Contramid® OAD (Prototype 2) First | Triticco® First | Desyrel® First |
|---|---|---|---|---|
| Started | 4 | 6 | 3 | 6 |
| Completed | 4 | 6 | 3 | 6 |
| Not completed | 0 | 0 | 0 | 0 |
AUC(0-t) = Area under the plasma concentration curve vs (versus) time data pairs, where t is the time of the last quantifiable concentration. Measured in nanogram x hours per milliliter (ng\*h/mL).
| ng*h/mL | Trazodone Contramid® OAD (Prototype 1) | Trazodone Contramid® OAD (Prototype 2) | Triticco® | Desyrel® |
|---|---|---|---|---|
| Bioequivalence Based on AUC(0-t) | 33883 ± 8069 | 32445 ± 8868 | 32928 ± 8313 | 31841 ± 7398 |
AUC(0-∞) = Area under the plasma concentration curve vs time data pairs, with extrapolation to infinity (∞). Measured in nanogram x hours per milliliter (ng\*h/mL).
| ng*h/mL | Trazodone Contramid® OAD (Prototype 1) | Trazodone Contramid® OAD (Prototype 2) | Triticco® | Desyrel® |
|---|---|---|---|---|
| Bioequivalence Based on AUC(0-∞) | 35122 ± 8655 | 33373 ± 9299 | 34165 ± 9105 | 32485 ± 7621 |
Cmax = Maximum plasma concentration. Measured in nanogram per milliliter (ng/mL).
| ng/mL | Trazodone Contramid® OAD (Prototype 1) | Trazodone Contramid® OAD (Prototype 2) | Triticco® | Desyrel® |
|---|---|---|---|---|
| Bioequivalence Based on Cmax | 1260 ± 402 | 1475 ± 489 | 1688 ± 442 | 2081 ± 492 |
Apparent terminal half-life (t½.z) of trazodone in hours
| Hours | Trazodone Contramid® OAD (Prototype 1) | Trazodone Contramid® OAD (Prototype 2) | Triticco® | Desyrel® |
|---|---|---|---|---|
| Apparent Terminal Half-life (t½.z) | 11.2 ± 3.92 | 10.9 ± 3.55 | 10.6 ± 3.25 | 9.77 ± 2.49 |
| Hours | Trazodone Contramid® OAD (Prototype 1) | Trazodone Contramid® OAD (Prototype 2) | Triticco® | Desyrel® |
|---|---|---|---|---|
| Time to the Maximum Concentration (Tmax) | 12.0 (3.00 to 24.0) | 6.00 (4.00 to 24.0) | 13.0 (2.00 to 16.0) | 8.50 (0.33 to 16.5) |
Apparent First order terminal rate constant \[λz\] of trazodone in plasma expressed in 1/hours.
| 1/hours | Trazodone Contramid® OAD (Prototype 1) | Trazodone Contramid® OAD (Prototype 2) | Triticco® | Desyrel® |
|---|---|---|---|---|
| Apparent First Order Terminal Rate Constant [λz] | 0.07 ± 0.02 | 0.07 ± 0.02 | 0.07 ± 0.02 | 0.08 ± 0.02 |
Non-serious events are listed at a 1% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Trazodone Contramid® OAD (Prototype 1) | — | 0/21 (0%) | 7/21 (33.3%) |
| Trazodone Contramid® OAD (Prototype 2) | — | 0/20 (0%) | 9/20 (45%) |
| Triticco® | — | 0/23 (0%) | 14/23 (60.9%) |
| Desyrel® | — | 0/21 (0%) | 14/21 (66.7%) |
| Event | Trazodone Contramid® OAD (Prototype 1) | Trazodone Contramid® OAD (Prototype 2) | Triticco® | Desyrel® |
|---|---|---|---|---|
| DizzinessNervous system disorders | 4/21 | 6/20 | 6/23 | 8/21 |
| HeadacheNervous system disorders | 2/21 | 1/20 | 4/23 | 6/21 |
| NauseaGastrointestinal disorders | 1/21 | 0/20 | 1/23 | 5/21 |
| FatigueGeneral disorders | 1/21 | 1/20 | 4/23 | 2/21 |
| Nasal congestionRespiratory, thoracic and mediastinal disorders | 0/21 | 1/20 | 3/23 | 1/21 |
| Dry mouthGastrointestinal disorders | 0/21 | 0/20 | 1/23 | 2/21 |
| NasopharyngitisInfections and infestations | 2/21 | 1/20 | 0/23 | 0/21 |
| Abdominal discomfortGastrointestinal disorders | 0/21 | 1/20 | 0/23 | 1/21 |
| SyncopeNervous system disorders | 0/21 | 1/20 | 1/23 | 0/21 |
| PalpitationsCardiac disorders | 1/21 | 0/20 | 0/23 | 0/21 |
| Age, Categorical(Participants) | Entire Study Population |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 24 |
| >=65 years | 0 |
| Age Continuous(years) | Entire Study Population |
|---|---|
| Mean | 24.9 ± 7.3 |
| Sex: Female, Male(Participants) | Entire Study Population |
|---|---|
| Female | 6 |
| Male | 18 |
| Region of Enrollment(participants) | Entire Study Population |
|---|---|
| South Africa | 24 |
No study locations are listed for this record.
The record gives a start of Mar 2005 and a primary completion of Apr 2005. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2010, 5 years 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Trazodone
Labopharm Inc.